查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1868004

体外注射器：全球市场份额和排名、总收入和需求预测（2025-2031年）

On-body Injectors - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 118 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球体表注射器市场规模估计为 1.78 亿美元，预计到 2031 年将达到 5.18 亿美元，在预测期（2025-2031 年）内以 16.5% 的复合年增长率增长。

本报告对近期与车载注射器相关的关税调整和国际战略反制措施进行了全面评估，包括跨境产业布局、资本配置模式、区域经济相互依存关係和供应链重组。

体外注射器，也称为体外给药系统（OBDS），是医疗设备，旨在在特定时间内内皮下（皮肤下）输送可控剂量的药物或治疗物质。这些装置通常佩戴在身上，用于输送各种治疗药物，包括药物、荷尔蒙和生物製药。体外注射器具有多项优势，包括提高患者便利性、改善依从性以及能够进行复杂的治疗方法。本研究的范围涵盖胰岛素以外的其他体外注射器。

2024 年，全球非胰岛素体外注射器的销售量将达到约 500 万台，平均市价为每台 35 美元。

北美目前是全球最大的可穿戴式註射器市场，这主要得益于其高昂的医疗保健支出、对先进药物传输技术的早期采用，以及安进（Neulasta® Onpro® 套装）等主要企业的强大影响力。美国在穿戴式药物传输系统的研发和核准处于主导，尤其是在癌症和自体免疫疾病等慢性病领域。新冠疫情后，居家治疗需求的增加和住院次数的减少进一步加速了市场扩张。

欧洲是外置注射器市场强劲且稳定的成长区域，主要得益于慢性病盛行率的上升、人口老化以及完善的医疗基础设施。德国、英国和法国等国是领先的采用者，部分原因是监管机构对以病人为中心的给药系统给予了支持。为了减轻医院负担并提高患者依从性，医疗机构正在积极采用穿戴式註射器，尤其是在生物製药和长期治疗方面。

亚太地区是体外注射剂市场成长最快的地区，这主要得益于人们健康意识的提高、中产阶级人口的壮大以及慢性病发病率的上升。中国、日本和韩国等国家正大力投资数位医疗和自我给药疗法。

本报告旨在对全球体表注射器市场进行全面分析，重点关注总销售量、收入、价格、企业市场占有率和主要企业的排名，并按地区/国家、类型和应用对体表注射器市场进行分析。

本报告以销售量（千台）和收入（百万美元）为单位，对体外注射器市场规模、估算和预测进行了呈现，基准年为2024年，并涵盖了2020年至2031年的历史数据和预测数据。报告采用定量和定性分析相结合的方法，帮助读者制定体外注射器业务/成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • West Pharmaceutical Services
  • Insulet
  • Gerresheimer
  • United Therapeutics
  • CC Bio
  • BD
  • Ypsomed
  • Enable Injections
  • Nemera
  • Stevanato Group
  • Sonceboz
  • Lohmann Therapie-Systeme
  • Elcam Drug Delivery Devices（E3D）
  • MicroMED
  • Altek Medical

按类型分類的细分市场

  • 电子注射器
  • 机械注射器

应用领域

  • 免疫肿瘤学
  • 心血管疾病
  • 神经系统疾病
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for On-body Injectors was estimated to be worth US$ 178 million in 2024 and is forecast to a readjusted size of US$ 518 million by 2031 with a CAGR of 16.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on On-body Injectors cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

On-body injectors, also known as on-body delivery systems (OBDS), are medical devices designed to deliver a controlled dose of medication or therapeutic substances subcutaneously (under the skin) over a specified period. These devices are typically worn on the body and are used to administer various treatments, including medications, hormones, and biologics. On-body injectors offer several advantages, including increased patient convenience, improved medication adherence, and the ability to deliver complex therapies. The scope of this report is non-insulin On-body injectors.

In 2024, the global sales ofnon-insulin on-body injectorsreached approximately5 million units, with an average market price of$35 per unit.

North America is currently the largest market for on-body injectors, driven by high healthcare spending, early adoption of advanced drug delivery technologies, and a strong presence of key players such as Amgen (with its Neulasta(R) Onpro(R) kit). The United States leads in the development and approval of wearable drug delivery systems, especially for chronic conditions like cancer and autoimmune diseases. Growing demand for home-based treatment and reduced hospital visits post-COVID-19 has further accelerated market expansion.

Europe is a strong and steadily growing market for on-body injectors, supported by rising prevalence of chronic diseases, aging populations, and robust healthcare infrastructure. Countries such as Germany, the UK, and France are key adopters, with regulatory support for patient-centric drug delivery systems. The focus on reducing hospital burden and improving patient compliance is encouraging healthcare providers to adopt wearable injectors, particularly for biologics and long-term therapies.

Asia-Pacific is the fastest-growing region for on-body injectors, driven by increasing healthcare awareness, expanding middle-class populations, and rising chronic disease incidence. Countries like China, Japan, and South Korea are investing heavily in digital health and self-administered therapies.

This report aims to provide a comprehensive presentation of the global market for On-body Injectors, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of On-body Injectors by region & country, by Type, and by Application.

The On-body Injectors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding On-body Injectors.

Market Segmentation

By Company

  • West Pharmaceutical Services
  • Insulet
  • Gerresheimer
  • United Therapeutics
  • CC Bio
  • BD
  • Ypsomed
  • Enable Injections
  • Nemera
  • Stevanato Group
  • Sonceboz
  • Lohmann Therapie-Systeme
  • Elcam Drug Delivery Devices (E3D)
  • MicroMED
  • Altek Medical

Segment by Type

  • Electronic Injectors
  • Mechanical Injectors

Segment by Application

  • Immuno-oncology
  • Cardiovascular Diseases
  • Neurological Diseases
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of On-body Injectors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of On-body Injectors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of On-body Injectors in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 On-body Injectors Product Introduction
  • 1.2 Global On-body Injectors Market Size Forecast
    • 1.2.1 Global On-body Injectors Sales Value (2020-2031)
    • 1.2.2 Global On-body Injectors Sales Volume (2020-2031)
    • 1.2.3 Global On-body Injectors Sales Price (2020-2031)
  • 1.3 On-body Injectors Market Trends & Drivers
    • 1.3.1 On-body Injectors Industry Trends
    • 1.3.2 On-body Injectors Market Drivers & Opportunity
    • 1.3.3 On-body Injectors Market Challenges
    • 1.3.4 On-body Injectors Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global On-body Injectors Players Revenue Ranking (2024)
  • 2.2 Global On-body Injectors Revenue by Company (2020-2025)
  • 2.3 Global On-body Injectors Players Sales Volume Ranking (2024)
  • 2.4 Global On-body Injectors Sales Volume by Company Players (2020-2025)
  • 2.5 Global On-body Injectors Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers On-body Injectors Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers On-body Injectors Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of On-body Injectors
  • 2.9 On-body Injectors Market Competitive Analysis
    • 2.9.1 On-body Injectors Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by On-body Injectors Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in On-body Injectors as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Electronic Injectors
    • 3.1.2 Mechanical Injectors
  • 3.2 Global On-body Injectors Sales Value by Type
    • 3.2.1 Global On-body Injectors Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global On-body Injectors Sales Value, by Type (2020-2031)
    • 3.2.3 Global On-body Injectors Sales Value, by Type (%) (2020-2031)
  • 3.3 Global On-body Injectors Sales Volume by Type
    • 3.3.1 Global On-body Injectors Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global On-body Injectors Sales Volume, by Type (2020-2031)
    • 3.3.3 Global On-body Injectors Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global On-body Injectors Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Immuno-oncology
    • 4.1.2 Cardiovascular Diseases
    • 4.1.3 Neurological Diseases
    • 4.1.4 Others
  • 4.2 Global On-body Injectors Sales Value by Application
    • 4.2.1 Global On-body Injectors Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global On-body Injectors Sales Value, by Application (2020-2031)
    • 4.2.3 Global On-body Injectors Sales Value, by Application (%) (2020-2031)
  • 4.3 Global On-body Injectors Sales Volume by Application
    • 4.3.1 Global On-body Injectors Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global On-body Injectors Sales Volume, by Application (2020-2031)
    • 4.3.3 Global On-body Injectors Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global On-body Injectors Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global On-body Injectors Sales Value by Region
    • 5.1.1 Global On-body Injectors Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global On-body Injectors Sales Value by Region (2020-2025)
    • 5.1.3 Global On-body Injectors Sales Value by Region (2026-2031)
    • 5.1.4 Global On-body Injectors Sales Value by Region (%), (2020-2031)
  • 5.2 Global On-body Injectors Sales Volume by Region
    • 5.2.1 Global On-body Injectors Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global On-body Injectors Sales Volume by Region (2020-2025)
    • 5.2.3 Global On-body Injectors Sales Volume by Region (2026-2031)
    • 5.2.4 Global On-body Injectors Sales Volume by Region (%), (2020-2031)
  • 5.3 Global On-body Injectors Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America On-body Injectors Sales Value, 2020-2031
    • 5.4.2 North America On-body Injectors Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe On-body Injectors Sales Value, 2020-2031
    • 5.5.2 Europe On-body Injectors Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific On-body Injectors Sales Value, 2020-2031
    • 5.6.2 Asia Pacific On-body Injectors Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America On-body Injectors Sales Value, 2020-2031
    • 5.7.2 South America On-body Injectors Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa On-body Injectors Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa On-body Injectors Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions On-body Injectors Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions On-body Injectors Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions On-body Injectors Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions On-body Injectors Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States On-body Injectors Sales Value, 2020-2031
    • 6.3.2 United States On-body Injectors Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States On-body Injectors Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe On-body Injectors Sales Value, 2020-2031
    • 6.4.2 Europe On-body Injectors Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe On-body Injectors Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China On-body Injectors Sales Value, 2020-2031
    • 6.5.2 China On-body Injectors Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China On-body Injectors Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan On-body Injectors Sales Value, 2020-2031
    • 6.6.2 Japan On-body Injectors Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan On-body Injectors Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea On-body Injectors Sales Value, 2020-2031
    • 6.7.2 South Korea On-body Injectors Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea On-body Injectors Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia On-body Injectors Sales Value, 2020-2031
    • 6.8.2 Southeast Asia On-body Injectors Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia On-body Injectors Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India On-body Injectors Sales Value, 2020-2031
    • 6.9.2 India On-body Injectors Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India On-body Injectors Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 West Pharmaceutical Services
    • 7.1.1 West Pharmaceutical Services Company Information
    • 7.1.2 West Pharmaceutical Services Introduction and Business Overview
    • 7.1.3 West Pharmaceutical Services On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 West Pharmaceutical Services On-body Injectors Product Offerings
    • 7.1.5 West Pharmaceutical Services Recent Development
  • 7.2 Insulet
    • 7.2.1 Insulet Company Information
    • 7.2.2 Insulet Introduction and Business Overview
    • 7.2.3 Insulet On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Insulet On-body Injectors Product Offerings
    • 7.2.5 Insulet Recent Development
  • 7.3 Gerresheimer
    • 7.3.1 Gerresheimer Company Information
    • 7.3.2 Gerresheimer Introduction and Business Overview
    • 7.3.3 Gerresheimer On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Gerresheimer On-body Injectors Product Offerings
    • 7.3.5 Gerresheimer Recent Development
  • 7.4 United Therapeutics
    • 7.4.1 United Therapeutics Company Information
    • 7.4.2 United Therapeutics Introduction and Business Overview
    • 7.4.3 United Therapeutics On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 United Therapeutics On-body Injectors Product Offerings
    • 7.4.5 United Therapeutics Recent Development
  • 7.5 CC Bio
    • 7.5.1 CC Bio Company Information
    • 7.5.2 CC Bio Introduction and Business Overview
    • 7.5.3 CC Bio On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 CC Bio On-body Injectors Product Offerings
    • 7.5.5 CC Bio Recent Development
  • 7.6 BD
    • 7.6.1 BD Company Information
    • 7.6.2 BD Introduction and Business Overview
    • 7.6.3 BD On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 BD On-body Injectors Product Offerings
    • 7.6.5 BD Recent Development
  • 7.7 Ypsomed
    • 7.7.1 Ypsomed Company Information
    • 7.7.2 Ypsomed Introduction and Business Overview
    • 7.7.3 Ypsomed On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Ypsomed On-body Injectors Product Offerings
    • 7.7.5 Ypsomed Recent Development
  • 7.8 Enable Injections
    • 7.8.1 Enable Injections Company Information
    • 7.8.2 Enable Injections Introduction and Business Overview
    • 7.8.3 Enable Injections On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Enable Injections On-body Injectors Product Offerings
    • 7.8.5 Enable Injections Recent Development
  • 7.9 Nemera
    • 7.9.1 Nemera Company Information
    • 7.9.2 Nemera Introduction and Business Overview
    • 7.9.3 Nemera On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Nemera On-body Injectors Product Offerings
    • 7.9.5 Nemera Recent Development
  • 7.10 Stevanato Group
    • 7.10.1 Stevanato Group Company Information
    • 7.10.2 Stevanato Group Introduction and Business Overview
    • 7.10.3 Stevanato Group On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Stevanato Group On-body Injectors Product Offerings
    • 7.10.5 Stevanato Group Recent Development
  • 7.11 Sonceboz
    • 7.11.1 Sonceboz Company Information
    • 7.11.2 Sonceboz Introduction and Business Overview
    • 7.11.3 Sonceboz On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 Sonceboz On-body Injectors Product Offerings
    • 7.11.5 Sonceboz Recent Development
  • 7.12 Lohmann Therapie-Systeme
    • 7.12.1 Lohmann Therapie-Systeme Company Information
    • 7.12.2 Lohmann Therapie-Systeme Introduction and Business Overview
    • 7.12.3 Lohmann Therapie-Systeme On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.12.4 Lohmann Therapie-Systeme On-body Injectors Product Offerings
    • 7.12.5 Lohmann Therapie-Systeme Recent Development
  • 7.13 Elcam Drug Delivery Devices (E3D)
    • 7.13.1 Elcam Drug Delivery Devices (E3D) Company Information
    • 7.13.2 Elcam Drug Delivery Devices (E3D) Introduction and Business Overview
    • 7.13.3 Elcam Drug Delivery Devices (E3D) On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.13.4 Elcam Drug Delivery Devices (E3D) On-body Injectors Product Offerings
    • 7.13.5 Elcam Drug Delivery Devices (E3D) Recent Development
  • 7.14 MicroMED
    • 7.14.1 MicroMED Company Information
    • 7.14.2 MicroMED Introduction and Business Overview
    • 7.14.3 MicroMED On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.14.4 MicroMED On-body Injectors Product Offerings
    • 7.14.5 MicroMED Recent Development
  • 7.15 Altek Medical
    • 7.15.1 Altek Medical Company Information
    • 7.15.2 Altek Medical Introduction and Business Overview
    • 7.15.3 Altek Medical On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.15.4 Altek Medical On-body Injectors Product Offerings
    • 7.15.5 Altek Medical Recent Development

8 Industry Chain Analysis

  • 8.1 On-body Injectors Industrial Chain
  • 8.2 On-body Injectors Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 On-body Injectors Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 On-body Injectors Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. On-body Injectors Market Trends
  • Table 2. On-body Injectors Market Drivers & Opportunity
  • Table 3. On-body Injectors Market Challenges
  • Table 4. On-body Injectors Market Restraints
  • Table 5. Global On-body Injectors Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global On-body Injectors Revenue Market Share by Company (2020-2025)
  • Table 7. Global On-body Injectors Sales Volume by Company (2020-2025) & (K Units)
  • Table 8. Global On-body Injectors Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market On-body Injectors Price by Company (2020-2025) & (US$/Unit)
  • Table 10. Key Manufacturers On-body Injectors Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers On-body Injectors Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of On-body Injectors
  • Table 13. Global On-body Injectors Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in On-body Injectors as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global On-body Injectors Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global On-body Injectors Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global On-body Injectors Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global On-body Injectors Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global On-body Injectors Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global On-body Injectors Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
  • Table 22. Global On-body Injectors Sales Volume by Type (2020-2025) & (K Units)
  • Table 23. Global On-body Injectors Sales Volume by Type (2026-2031) & (K Units)
  • Table 24. Global On-body Injectors Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global On-body Injectors Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global On-body Injectors Price by Type (2020-2025) & (US$/Unit)
  • Table 27. Global On-body Injectors Price by Type (2026-2031) & (US$/Unit)
  • Table 28. Global On-body Injectors Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global On-body Injectors Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global On-body Injectors Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global On-body Injectors Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global On-body Injectors Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global On-body Injectors Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
  • Table 34. Global On-body Injectors Sales Volume by Application (2020-2025) & (K Units)
  • Table 35. Global On-body Injectors Sales Volume by Application (2026-2031) & (K Units)
  • Table 36. Global On-body Injectors Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global On-body Injectors Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global On-body Injectors Price by Application (2020-2025) & (US$/Unit)
  • Table 39. Global On-body Injectors Price by Application (2026-2031) & (US$/Unit)
  • Table 40. Global On-body Injectors Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global On-body Injectors Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global On-body Injectors Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global On-body Injectors Sales Value by Region (2020-2025) & (%)
  • Table 44. Global On-body Injectors Sales Value by Region (2026-2031) & (%)
  • Table 45. Global On-body Injectors Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
  • Table 46. Global On-body Injectors Sales Volume by Region (2020-2025) & (K Units)
  • Table 47. Global On-body Injectors Sales Volume by Region (2026-2031) & (K Units)
  • Table 48. Global On-body Injectors Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global On-body Injectors Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global On-body Injectors Average Price by Region (2020-2025) & (US$/Unit)
  • Table 51. Global On-body Injectors Average Price by Region (2026-2031) & (US$/Unit)
  • Table 52. Key Countries/Regions On-body Injectors Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions On-body Injectors Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions On-body Injectors Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions On-body Injectors Sales Volume, (2020-2025) & (K Units)
  • Table 56. Key Countries/Regions On-body Injectors Sales Volume, (2026-2031) & (K Units)
  • Table 57. West Pharmaceutical Services Company Information
  • Table 58. West Pharmaceutical Services Introduction and Business Overview
  • Table 59. West Pharmaceutical Services On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 60. West Pharmaceutical Services On-body Injectors Product Offerings
  • Table 61. West Pharmaceutical Services Recent Development
  • Table 62. Insulet Company Information
  • Table 63. Insulet Introduction and Business Overview
  • Table 64. Insulet On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 65. Insulet On-body Injectors Product Offerings
  • Table 66. Insulet Recent Development
  • Table 67. Gerresheimer Company Information
  • Table 68. Gerresheimer Introduction and Business Overview
  • Table 69. Gerresheimer On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 70. Gerresheimer On-body Injectors Product Offerings
  • Table 71. Gerresheimer Recent Development
  • Table 72. United Therapeutics Company Information
  • Table 73. United Therapeutics Introduction and Business Overview
  • Table 74. United Therapeutics On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 75. United Therapeutics On-body Injectors Product Offerings
  • Table 76. United Therapeutics Recent Development
  • Table 77. CC Bio Company Information
  • Table 78. CC Bio Introduction and Business Overview
  • Table 79. CC Bio On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 80. CC Bio On-body Injectors Product Offerings
  • Table 81. CC Bio Recent Development
  • Table 82. BD Company Information
  • Table 83. BD Introduction and Business Overview
  • Table 84. BD On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 85. BD On-body Injectors Product Offerings
  • Table 86. BD Recent Development
  • Table 87. Ypsomed Company Information
  • Table 88. Ypsomed Introduction and Business Overview
  • Table 89. Ypsomed On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 90. Ypsomed On-body Injectors Product Offerings
  • Table 91. Ypsomed Recent Development
  • Table 92. Enable Injections Company Information
  • Table 93. Enable Injections Introduction and Business Overview
  • Table 94. Enable Injections On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 95. Enable Injections On-body Injectors Product Offerings
  • Table 96. Enable Injections Recent Development
  • Table 97. Nemera Company Information
  • Table 98. Nemera Introduction and Business Overview
  • Table 99. Nemera On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 100. Nemera On-body Injectors Product Offerings
  • Table 101. Nemera Recent Development
  • Table 102. Stevanato Group Company Information
  • Table 103. Stevanato Group Introduction and Business Overview
  • Table 104. Stevanato Group On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 105. Stevanato Group On-body Injectors Product Offerings
  • Table 106. Stevanato Group Recent Development
  • Table 107. Sonceboz Company Information
  • Table 108. Sonceboz Introduction and Business Overview
  • Table 109. Sonceboz On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 110. Sonceboz On-body Injectors Product Offerings
  • Table 111. Sonceboz Recent Development
  • Table 112. Lohmann Therapie-Systeme Company Information
  • Table 113. Lohmann Therapie-Systeme Introduction and Business Overview
  • Table 114. Lohmann Therapie-Systeme On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 115. Lohmann Therapie-Systeme On-body Injectors Product Offerings
  • Table 116. Lohmann Therapie-Systeme Recent Development
  • Table 117. Elcam Drug Delivery Devices (E3D) Company Information
  • Table 118. Elcam Drug Delivery Devices (E3D) Introduction and Business Overview
  • Table 119. Elcam Drug Delivery Devices (E3D) On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 120. Elcam Drug Delivery Devices (E3D) On-body Injectors Product Offerings
  • Table 121. Elcam Drug Delivery Devices (E3D) Recent Development
  • Table 122. MicroMED Company Information
  • Table 123. MicroMED Introduction and Business Overview
  • Table 124. MicroMED On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 125. MicroMED On-body Injectors Product Offerings
  • Table 126. MicroMED Recent Development
  • Table 127. Altek Medical Company Information
  • Table 128. Altek Medical Introduction and Business Overview
  • Table 129. Altek Medical On-body Injectors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 130. Altek Medical On-body Injectors Product Offerings
  • Table 131. Altek Medical Recent Development
  • Table 132. Key Raw Materials Lists
  • Table 133. Raw Materials Key Suppliers Lists
  • Table 134. On-body Injectors Downstream Customers
  • Table 135. On-body Injectors Distributors List
  • Table 136. Research Programs/Design for This Report
  • Table 137. Key Data Information from Secondary Sources
  • Table 138. Key Data Information from Primary Sources

List of Figures

  • Figure 1. On-body Injectors Product Picture
  • Figure 2. Global On-body Injectors Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global On-body Injectors Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global On-body Injectors Sales Volume (2020-2031) & (K Units)
  • Figure 5. Global On-body Injectors Sales Price (2020-2031) & (US$/Unit)
  • Figure 6. On-body Injectors Report Years Considered
  • Figure 7. Global On-body Injectors Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global On-body Injectors Players Sales Volume Ranking (2024) & (K Units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by On-body Injectors Revenue in 2024
  • Figure 10. On-body Injectors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Electronic Injectors Picture
  • Figure 12. Mechanical Injectors Picture
  • Figure 13. Global On-body Injectors Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global On-body Injectors Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Global On-body Injectors Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
  • Figure 16. Global On-body Injectors Sales Volume Market Share by Type, 2024 & 2031
  • Figure 17. Global On-body Injectors Price by Type (2020-2031) & (US$/Unit)
  • Figure 18. Product Picture of Immuno-oncology
  • Figure 19. Product Picture of Cardiovascular Diseases
  • Figure 20. Product Picture of Neurological Diseases
  • Figure 21. Product Picture of Others
  • Figure 22. Global On-body Injectors Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 23. Global On-body Injectors Sales Value Market Share by Application, 2024 & 2031
  • Figure 24. Global On-body Injectors Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
  • Figure 25. Global On-body Injectors Sales Volume Market Share by Application, 2024 & 2031
  • Figure 26. Global On-body Injectors Price by Application (2020-2031) & (US$/Unit)
  • Figure 27. North America On-body Injectors Sales Value (2020-2031) & (US$ Million)
  • Figure 28. North America On-body Injectors Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Europe On-body Injectors Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. Europe On-body Injectors Sales Value by Country (%), 2024 VS 2031
  • Figure 31. Asia Pacific On-body Injectors Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Asia Pacific On-body Injectors Sales Value by Region (%), 2024 VS 2031
  • Figure 33. South America On-body Injectors Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. South America On-body Injectors Sales Value by Country (%), 2024 VS 2031
  • Figure 35. Middle East & Africa On-body Injectors Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. Middle East & Africa On-body Injectors Sales Value by Country (%), 2024 VS 2031
  • Figure 37. Key Countries/Regions On-body Injectors Sales Value (%), (2020-2031)
  • Figure 38. Key Countries/Regions On-body Injectors Sales Volume (%), (2020-2031)
  • Figure 39. United States On-body Injectors Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. United States On-body Injectors Sales Value by Type (%), 2024 VS 2031
  • Figure 41. United States On-body Injectors Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Europe On-body Injectors Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Europe On-body Injectors Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Europe On-body Injectors Sales Value by Application (%), 2024 VS 2031
  • Figure 45. China On-body Injectors Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. China On-body Injectors Sales Value by Type (%), 2024 VS 2031
  • Figure 47. China On-body Injectors Sales Value by Application (%), 2024 VS 2031
  • Figure 48. Japan On-body Injectors Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. Japan On-body Injectors Sales Value by Type (%), 2024 VS 2031
  • Figure 50. Japan On-body Injectors Sales Value by Application (%), 2024 VS 2031
  • Figure 51. South Korea On-body Injectors Sales Value, (2020-2031) & (US$ Million)
  • Figure 52. South Korea On-body Injectors Sales Value by Type (%), 2024 VS 2031
  • Figure 53. South Korea On-body Injectors Sales Value by Application (%), 2024 VS 2031
  • Figure 54. Southeast Asia On-body Injectors Sales Value, (2020-2031) & (US$ Million)
  • Figure 55. Southeast Asia On-body Injectors Sales Value by Type (%), 2024 VS 2031
  • Figure 56. Southeast Asia On-body Injectors Sales Value by Application (%), 2024 VS 2031
  • Figure 57. India On-body Injectors Sales Value, (2020-2031) & (US$ Million)
  • Figure 58. India On-body Injectors Sales Value by Type (%), 2024 VS 2031
  • Figure 59. India On-body Injectors Sales Value by Application (%), 2024 VS 2031
  • Figure 60. On-body Injectors Industrial Chain
  • Figure 61. On-body Injectors Manufacturing Cost Structure
  • Figure 62. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 63. Bottom-up and Top-down Approaches for This Report
  • Figure 64. Data Triangulation
  • Figure 65. Key Executives Interviewed